# A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

> **NCT05036512** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 129 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** GBT021601

## Key facts

- **NCT ID:** NCT05036512
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-09
- **Primary completion:** 2022-11-02
- **Final completion:** 2023-02-07
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2023-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05036512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05036512, "A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05036512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*